




FIG. 1B










FIG. 3

Date of Mailing: 09 22/2003






FIG. 4








FIG. 5C

Filed: 03/02/2001 Inventors: Wagner et al.

Attorney's Docket No.: C1041.70010US00 Date of Mailing: 09/22/2003




FIG. 6A





FIG. 6B









FIG. 8







Inventors: Wagner et al. Attorney s Docket No.: C1041.70010US00

Date of Mailing: 09/22/2003










FIG. 12




FIG. 13

# Serial No.: 09/786,436 Entitled: G-MOTIF OLIGONUCLEOTIDES AND USES THEREOF Filed: 03/02/2001 Inventors: Wagner et al. Attorney's Docket No.: C1041.70010US00 Date of Mailing: 09/22/2003

Sequence specificity of GR1 binding activity: oligonucleotide SP1 and EGR1 compete, while 1668 and NFkB do not

Proteinase K treatment abolishes binding activity




FIG. 14

### Serial No.: 09:786,436 Entitled: G-MOTIF OLIGONUCLEOTIDES AND USES THEREOF Filed: 03/02/2001 Inventors: Wagner et al.

Attorney's Docket No.: C1041.70010US00
Date of Mailing: 09/22/2003

# UV-Crosslink of ssODN GR1 to protein extracts of J774 cells: specific binding to 25 kDa and 58 kDa proteins




FIG. 15